Kiyean Nam

1.3k total citations
24 papers, 458 citations indexed

About

Kiyean Nam is a scholar working on Molecular Biology, Infectious Diseases and Oncology. According to data from OpenAlex, Kiyean Nam has authored 24 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Infectious Diseases and 6 papers in Oncology. Recurrent topics in Kiyean Nam's work include Tuberculosis Research and Epidemiology (7 papers), Cancer therapeutics and mechanisms (6 papers) and Phagocytosis and Immune Regulation (5 papers). Kiyean Nam is often cited by papers focused on Tuberculosis Research and Epidemiology (7 papers), Cancer therapeutics and mechanisms (6 papers) and Phagocytosis and Immune Regulation (5 papers). Kiyean Nam collaborates with scholars based in United States, South Korea and Switzerland. Kiyean Nam's co-authors include Wendy D. Cornell, Jaeseung Kim, Paul R. Marshall, Young Mi Kim, Sun‐Hee Kang, Min Jung Seo, Hwankyu Kang, Christian Honer, Christoph Schumacher and Zaesung No and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Cancer Research.

In The Last Decade

Kiyean Nam

24 papers receiving 441 citations

Peers

Countries citing papers authored by Kiyean Nam

Since Specialization

Citations

This map shows the geographic impact of Kiyean Nam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kiyean Nam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kiyean Nam more than expected).

Fields of papers citing papers by Kiyean Nam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kiyean Nam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kiyean Nam. The network helps show where Kiyean Nam may publish in the future.

Co-authorship network of co-authors of Kiyean Nam

This figure shows the co-authorship network connecting the top 25 collaborators of Kiyean Nam. A scholar is included among the top collaborators of Kiyean Nam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kiyean Nam. Kiyean Nam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond 2025 ·American Journal of Respiratory and Critical Care Medicine ·Saskia Janssen, Caryn M. Upton, Veronique de Jager, Christo van Niekerk, (unknown), (unknown), Jeongjun Kim, Jin‐Ho Choi, Kiyean Nam, Eugene Sun, Andreas H. Diacon	3
2	A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009). 2024 ·Journal of Clinical Oncology ·Hao Xie, Anthony B. El-Khoueiry, Angela Alistar, Hani M. Babiker, Devalingam Mahalingam, Minal Barve, Joohyuk Sohn, Mitesh J. Borad, Jae-Cheol Lee, (unknown), (unknown), Jin‐Ho Choi, Jeongjun Kim, Donghoon Yu, Seungjoo Lee, (unknown), Stefan Proniuk, Jaeseung Kim, Kiyean Nam	2
3	An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity 2024 ·Pharmaceutics ·(unknown), Sabrina Wagner, Martin Schütz, (unknown), (unknown), Jaeseung Kim, (unknown), (unknown), Julia Tillmanns, Christina Wangen, Friedrich Hahn, Benedikt B. Kaufer, Frank Neipel, Jan Eickhoff, Bert Klebl, Kiyean Nam, Manfred Marschall	6
4	Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203) 2023 ·Biomedicine & Pharmacotherapy ·Jeongjun Kim, Tae‐Hwan Kim, Jin‐Ho Choi, Kiyean Nam, Beom Soo Shin, Soyoung Shin	1
5	Abstract 2255: Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors 2023 ·Cancer Research ·(unknown), (unknown), Angela Alistar, Anthony B. El-Khoueiry, Alain C. Mita, Hwankyu Kang, Jin‐Ho Choi, (unknown), Jeongjun Kim, Seungjoo Lee, Yeong‐In Yang, (unknown), (unknown), Jaeseung Kim, Kiyean Nam	2
6	Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial 2022 ·Antimicrobial Agents and Chemotherapy ·Jeongjun Kim, Jin‐Ho Choi, Hwankyu Kang, (unknown), (unknown), Christo van Niekerk, Jaeseung Kim, (unknown), Kiyean Nam, Tae‐Hwan Kim, Beom Soo Shin, Soyoung Shin	11
7	A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors. 2021 ·Journal of Clinical Oncology ·Angela Alistar, Anthony B. El-Khoueiry, Devalingam Mahalingam, Monica Mita, Hwankyu Kang, Yeong‐In Yang, (unknown), Jeongjun Kim, (unknown), (unknown), (unknown), (unknown), Jaeseung Kim, Kiyean Nam	1
8	Abstract 1953: Q901, a selective CDK7 inhibitor, a potential new strategy for primary and CDK4/6 inhibitor resistant ER-positive breast cancer 2021 ·Cancer Research ·Donghoon Yu, (unknown), (unknown), (unknown), (unknown), Jaeseung Kim, Kiyean Nam	4
9	Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects 2021 ·Antimicrobial Agents and Chemotherapy ·Jeongjun Kim, Jin‐Ho Choi, Hwankyu Kang, (unknown), (unknown), Christo van Niekerk, (unknown), Jaeseung Kim, (unknown), Kiyean Nam, Soyoung Shin, Beom Soo Shin	19
10	Abstract 4855: Development of highly selective CDK7 inhibitor Q901 for solid tumors 2020 ·Cancer Research ·Donghoon Yu, (unknown), (unknown), (unknown), (unknown), Jaeseung Kim, Choa Park, Euna Jeong, Sukjoon Yoon, Kiyean Nam	4
11	Abstract 4139: Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy 2019 ·Cancer Research ·Yeong‐In Yang, Hwankyu Kang, (unknown), (unknown), Jeongjun Kim, (unknown), Jaeseung Kim, (unknown), Jae-Cheol Lee, Kiyean Nam	3
12	Synthesis and structure-activity relationships of novel fused ring analogues of Q203 as antitubercular agents 2017 ·European Journal of Medicinal Chemistry ·Sun‐Hee Kang, Young Mi Kim, Hee-Kyung Jeon, Se-Jin Park, Min Jung Seo, Saeyeon Lee, (unknown), (unknown), Seokwoo Lee, Kiyean Nam, Sanghee Kim, Jaeseung Kim	23
13	Synthesis and structure-activity studies of side chain analogues of the anti-tubercular agent, Q203 2016 ·European Journal of Medicinal Chemistry ·Sun‐Hee Kang, Young Mi Kim, (unknown), Min Jung Seo, Zaesung No, Kiyean Nam, Sanghee Kim, Jaeseung Kim	31
14	Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent 2014 ·Journal of Medicinal Chemistry ·Sun‐Hee Kang, (unknown), Min Jung Seo, Saeyeon Lee, Young Mi Kim, (unknown), Jeong Jea Seo, Yoonae Ko, Inhee Choi, Jichan Jang, Jiyoun Nam, Sei Jin Park, Hwankyu Kang, Hyung Jun Kim, Jungjun Kim, Sujin Ahn, Kévin Pethe, Kiyean Nam, Zaesung No, Jaeseung Kim	149
15	Steroid Hormone Binding Receptors: Application of Homology Modeling, Induced Fit Docking, and Molecular Dynamics to Study Structure- Function Relationships 2009 ·Current Topics in Medicinal Chemistry ·Wendy D. Cornell, Kiyean Nam	10
16	Dynamic control of allosteric antagonism of leukocyte function antigen‐1 and intercellular adhesion molecule‐1 interaction 2006 ·Proteins Structure Function and Bioinformatics ·Kiyean Nam, Vladimir N. Maiorov, Bradley P. Feuston, Simon K. Kearsley	8
17	p38 MAP kinase inhibitors. Part 6: 2-Arylpyridazin-3-ones as templates for inhibitor design 2006 ·Bioorganic & Medicinal Chemistry Letters ·S. Natarajan, Stephen T. Heller, Kiyean Nam, Suresh B. Singh, Giovanna Scapin, Sangita B. Patel, James E. Thompson, Catherine E. Fitzgerald, Stephen J. O’Keefe	19
18	Structural components of SCAN‐domain dimerizations 2004 ·Proteins Structure Function and Bioinformatics ·Kiyean Nam, Christian Honer, Christoph Schumacher	13
19	Glucocorticoid Receptor Antagonism by Cyproterone Acetate and RU486 2003 ·Molecular Pharmacology ·Christian Honer, Kiyean Nam, Cynthia A. Fink, Paul R. Marshall, Gary M. Ksander, (unknown), Wendy D. Cornell, Ronald E. Steele, Robert Schweitzer, Christoph Schumacher	78
20	Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor α and estrogen‐related receptor γ 2002 ·Biopolymers ·Kiyean Nam, Paul R. Marshall, Romain M. Wolf, Wendy D. Cornell	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact